CALIXAR team will be present at the online European Antibody Engineering & Therapeutics from June 07 to 09, 2022 to discuss about commercial and scientific opportunities linked to our activities.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
About Antibody Engineering & Therapeutics Europe
Organized by the Antibody Society, the Antibody Engineering & Therapeutics conference is dedicated to scientists to exchange and network in the fields of antibody engineering and therapeutics, immune-biology, and next-generation binders. This is the Europe’s leading antibody conference for accelerating next-generation antibodies to commercial success. The conference includes 8 new hot topic streams.
To meet us and discover the agenda: Antibody Engineering & Therapeutics Europe